Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab
administered as first-line treatment of previously untreated elderly patients, older than 70
years, with metastatic or locally recurrent breast cancer.